Definitive Contract 75F40121C00111
Award Date
8/20/21
Potential Completion Date
8/31/25
Potential Value
$5M
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $5,000,001.00 definitive contract awarded by the Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) for "APPLICATION OF SMART DATA ANALYTICS FOR BIOMANUFACTURING." The contract has no set-aside designation and is a cost-type contract without fee. The contract was awarded under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research and development proposals across various regulatory science areas to...
This $4,714,475.00 definitive, firm-fixed-price federal contract was awarded by the U.S. Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) to conduct research and development on mechanistic modeling and process analytical technology for exosome production. The work is being performed in Cambridge, Massachusetts and will be completed by September 29, 2026. This contract was competitively awarded and is not designated as a set-aside. The original solicitation...
This federal contract award, valued at $6,038,686.00, was issued by the Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) to generate a Broad Agency Announcement (BAA) addressing the ongoing growth in continuous manufacturing within cell lines. The requirement is being funded through the President's initiative to focus on advanced manufacturing. This is a definitive, firm-fixed-price contract with a period of performance through September 29, 2027. No...
This federal contract, awarded by the Food and Drug Administration (FDA), provides $2,565,626.00 to the Massachusetts Institute of Technology (MIT) to conduct research and development on "Technologies to Enable Continuous Production of RAAV from SF9/Baculovirus Culture". The contract has no set-aside designation. The work is being performed under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which seeks proposals across eight areas of regulatory science to...
This federal contract award, valued at $4,835,002, was made by the Food and Drug Administration (FDA) to The Mitre Corporation, a not-for-profit organization that operates federally funded research and development centers. The contract is for system engineering and acquisitions support for the FDA's Office of Acquisitions and Grants Services (OAGS). This is a cost-plus-fixed-fee delivery order contract with a period of performance ending on September 29, 2017. The contract was not set aside...
This is a $13,010,622.00 cost-plus-fixed-fee delivery order contract awarded by the Food and Drug Administration (FDA) to The Mitre Corporation, a non-profit organization. The contract is for the FDA's Center for Biologics Evaluation and Research (CBER) Biologic Effectiveness and Safety (BEST) Innovative Methods (IM) program. The contract does not have a set-aside designation. Mitre, as a federally funded research and development center (FFRDC), will provide scientific, technical, and...
This is a $4,098,198.00 delivery order contract awarded by the Food and Drug Administration (FDA) to The Mitre Corporation, a non-profit federally funded research and development center (FFRDC). The contract is for systems engineering and technical services to support the FDA's Center for Food Safety and Applied Nutrition (CFSAN) IT portfolio and architecture. The contract is not set aside and was awarded under Mitre's existing HEALTH FFRDC contract with the Centers for Medicare and Medicaid...
This is a cost-plus-fixed-fee delivery order for $4,726,928.00 awarded by the Food and Drug Administration (FDA) to The Mitre Corporation, a non-profit organization that operates federally funded research and development centers. The contract is for research and technical support related to pathogen reduction technologies (PRT) for the FDA's Center for Biologics Evaluation and Research (CBER). The contract has no set-aside designation. The Mitre Corporation has extensive experience supporting...
This federal contract award is for BIOMEDICAL (APPLIED/EXPLORATORY) research and development work, with a ceiling value of $621,724.00. The contract was awarded by the U.S. government to the Massachusetts Institute of Technology (MIT) on April 1, 2009, with a planned completion date of December 31, 2009. The contract is part of the GENOMIC SEQUENCING CENTERS FOR INFECTIOUS DISEASES major program and is a definitive contract with a cost-no-fee pricing type. The work is being performed in...
This is a federal contract award to The Mitre Corporation, a non-profit organization that operates federally funded research and development centers (FFRDCs), to provide systems engineering and technical acquisitions support services to the U.S. Food and Drug Administration (FDA). The contract has a ceiling value of $5,859,996.00 and runs from September 30, 2015 to December 21, 2016. It is a Cost Plus Fixed Fee contract type. The Mitre Corporation has been awarded multiple federal contracts...